germanium and Lymphoma

germanium has been researched along with Lymphoma* in 8 studies

Other Studies

8 other study(ies) available for germanium and Lymphoma

ArticleYear
The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).
    Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 2016, Volume: 32, Issue:5

    The quantitative assessment of Positron Emission Tomography (PET) scans using standardized uptake value and derived parameters proved to be superior to traditional qualitative assessment in several retrospective or mono-centric prospective reports. Since different scanners give different quantitative readings, a program for clinical trial qualification (CTQ) is mandatory to guarantee a reliable and reproducible use of quantitative PET in prospective multi-centre clinical trials and in every-day clinical life.. We set up, under the auspices of Italian Foundation on Lymphoma (FIL), a CTQ program consisting of the PET/CT scan acquisition and analysis of (18)F and (68)Ge NEMA/IEC image quality phantoms for the reduction of inter-scanner variability. Variability was estimated on background activity concentration (BAC) and sphere to background ratio (SBR).. The use of a (68)Ge phantom allowed reducing the inter-scanner variability among different scanners from 74.0% to 20.5% in BAC and from 63.3% to 17.4% in SBR compared to using the (18)F phantom. The CTQ criteria were fulfilled at first round in 100% and 28% of PET scanners with (68)Ge and (18)F respectively.. The (68)Ge phantom proved a reliable tool for PET scanner qualification, able to significantly reduce the potential sources of error while increasing the reproducibility of PET derived quantitative parameter measurement.

    Topics: Calibration; Clinical Trials as Topic; Equipment Design; Fluorodeoxyglucose F18; Germanium; Humans; Image Processing, Computer-Assisted; Lymphoma; Multicenter Studies as Topic; Patient Selection; Phantoms, Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radioisotopes; Reproducibility of Results; Retrospective Studies

2016
Phase II Eastern Cooperative Oncology Group Study of spirogermanium in previously treated lymphoma.
    Cancer treatment reports, 1986, Volume: 70, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Germanium; Humans; Lymphoma; Middle Aged; Organometallic Compounds; Seizures; Spiro Compounds

1986
A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study.
    Investigational new drugs, 1985, Volume: 3, Issue:3

    The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to patients with poor prognosis non-Hodgkin's lymphomas. All patients had had a maximum of one prior treatment regimen. No responses were seen in 13 evaluable patients. Toxicity was primarily neurologic and mild or moderate in most patients. There is no evidence of activity of spirogermanium given in this schedule in this subset of lymphoma patients.

    Topics: Aged; Antineoplastic Agents; Drug Evaluation; Germanium; Humans; Lymphoma; Middle Aged; Nervous System Diseases; Organometallic Compounds; Prognosis; Spiro Compounds

1985
[Effects of interferon and its inducers on neutrophil chemiluminescence].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:7

    In order to evaluate effects of interferon (IFN) and its inducers on neutrophil functions, neutrophil chemiluminescence (ChL) was assayed in 12 patients treated with IFN (human lymphoblastoid interferon, 3.0 X 10(6) units/day i.m. daily) or Ge-132 (2,250 mg/day p.o. daily). The peak levels of neutrophil ChL, assayed one week after the initiation of treatment, were increased in comparison to those before treatment, but one month after treatment they were decreased to pretreatment levels in spite of the daily administration of the agent. On the basis of these results, it was concluded that IFN and Ge-132 enhanced the host defence mechanism including the activation of neutrophils, which appeared at the early phase of the host reaction.

    Topics: Adenocarcinoma; Adult; Aged; Female; Germanium; Humans; Interferon Inducers; Interferon Type I; Kidney Neoplasms; Leukemia, Myeloid; Luminescent Measurements; Lymphoma; Male; Middle Aged; Multiple Myeloma; Neutrophils; Organometallic Compounds; Oxygen Consumption; Phagocytosis; Propionates

1984
Pulmonary toxicity associated with spirogermanium.
    Cancer treatment reports, 1984, Volume: 68, Issue:6

    Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Evaluation; Female; Germanium; Humans; Lung Diseases; Lymphoma; Male; Middle Aged; Organometallic Compounds; Spiro Compounds

1984
Phase I study of spirogermanium given daily.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:5

    Spirogermanium, an azaspirane compound, has recently had limited clinical trials using a schedule of intravenous injection one to three times every week. The observation of clinical antitumor activity and lack of myelosuppression prompted us to investigate further the clinical effects of spirogermanium administered on various schedules. A total of 52 patients with advanced metastatic tumors refractory to standard therapy were treated with spirogermanium. Three different schedules of drug administration were evaluated. Initially, a short daily IV infusion for 5 days every week was evaluated, starting with a dose of 30 mg/m2/day. A total of 22 patients received 69 courses with a dose range of 30-120 mg/m2/day for 5 days every week. The maximum tolerated dose was 100 mg/m2/day IV over 1 hr and 120 mg/m2 over 2-3 hr. In the second phase of the study, 12 patients received 41 courses of spirogermanium as a 24-hr continuous infusion for 5 days/wk at a dose of 150-375 mg/m2/day. The maximum tolerated dose was 200 mg/m2/day for 5 days. In the third phase of the study, 18 patients received spirogermanium as a continuous infusion daily for a median of 30 days (range 6-77 days) in a dose range of 100-200 mg/m2/day. The maximum tolerated dose was 150 mg/m2/day. Of the 44 assessable patients, 3 demonstrated a partial response and 3 had minor tumor regression; all responses occurred in lymphoma patients. The dose-limiting toxicity of spirogermanium was neurologic; other side effects consisted of mild anorexia, nausea and vomiting, and possible lung toxicity. There was no clear evidence of cumulative toxicity despite daily administration of spirogermanium. Our data suggest that spirogermanium can be administered daily by several different schedules, and the optimum dose depends on the infusion time and the duration of therapy. The delivery of drug by continuous infusion permitted administration of twofold higher dose levels compared to the standard IV schedules used in previous studies.

    Topics: Adult; Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Germanium; Humans; Infusions, Parenteral; Lymphoma; Male; Middle Aged; Nausea; Nervous System Diseases; Organometallic Compounds; Ovarian Neoplasms; Spiro Compounds

1983
Spirogermanium: effects on hematopoietic stem cells and survival of normal and tumor-bearing mice.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1983, Volume: 173, Issue:2

    The effect of spirogermanium (SG) on hematopoietic stem cells, tumor burden, and survival times was investigated in C3H mice with transplanted mammary carcinoma. Compared to normal mice, the number of hematopoietic stem cells, or colony-forming units per spleen (CFU-S), was lower in the marrow of tumor-bearing mice. Spirogermanium at 15 and 30 mg/kg was not toxic to the normal hematopoietic cells in the marrow of either normal or tumor-bearing mice. In contrast to animals treated with cyclophosphamide, SG did not decrease the tumor growth rate or prolong the survival times of tumor-bearing C3H mice. Doses of 35-40 mg/kg SG did not prolong the survival times or decrease the tumor burden of AKR/J mice with a long-passaged lymphoma. These studies demonstrate that SG has minimal inhibitory effects to the marrow of normal mice and may promote the maintenance of normal marrow cells in tumor-bearing animals. However, in two different transplanted tumor cell lines, SG did not inhibit tumor growth or prolong host survival time.

    Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Female; Germanium; Hematopoietic Stem Cells; Lymphoma; Mammary Neoplasms, Experimental; Mice; Mice, Inbred AKR; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Organometallic Compounds; Spiro Compounds; Spleen

1983
A model to study drug effects on lymphoma and normal cell populations using the AKR/J mouse.
    Leukemia research, 1982, Volume: 6, Issue:2

    The existence of an AKR subline, AKR(Rb6.15)1A1d, with a chromosome marker provided a means to differentiate between proliferating lymphoma and normal cell populations within a single animal. An AKR(Rb6.15)1A1d lymphoma cell line has been maintained for 6 yr by serial passage in AKR/J recipients. The mice die in 7 +/- 2.0 days with evidence of extensive infiltration of the tissues by lymphoma cells. Cytogenetic analysis showed that approx. 1% of the metaphase cells in the bone marrow of mice at day 1 of the lymphoma passage were of the AKR(Rb6.15)1A1d donor-type. This increased to 54% by day 4 and 96% by day 6. The number of donor-type metaphase cells per humerus increased from 3.4 +/- 0.29 (X 10(3] at day 1 to 2.0 +/- 0.49 (X 10(5] at day 4 with a concomitant decrease in the number of non-lymphoma host-type metaphase cells. The population doubling time of donor-type metaphase cells per humerus was 12 +/- 1.4 h. At day 4, there was a significant decrease in the percentage of donor-type metaphase cells in mice that had been treated with BCNU (19.0 +/- 5.85%) or spirogermanium (38.6 +/- 5.85%) 24 h earlier. For BCNU treated animals, this also represented a decrease to 4.4 +/- 1.1 (X 10(4] donor-type metaphase cells per humerus.

    Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Germanium; Karyotyping; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred AKR; Neoplasm Transplantation; Organometallic Compounds; Spiro Compounds

1982